Search
Bacampicillin
go.drugbank.com/drugs/DB01602ApprovedWithdrawnIt is microbiologically active as ampicillin, and exerts a bactericidal action through the inhibition of the biosynthesis of cell wall mucopeptides.
Laromustine
go.drugbank.com/drugs/DB05817InvestigationalVNP40101M is a novel alkylating agent that has been used in trials studying the treatment of Leukemia, Lymphoma, Lung Cancer, Small Intestine Cancer, and Myelodysplastic Syndromes, among others.
Ragweed pollen extract
go.drugbank.com/drugs/DB05368ApprovedWithdrawnRagweed pollen extract has been developed by Curalogic. The company has initiated a phase III trial with its product for oral immunotherapy of ragweed allergy. … While traditional disease-modifying immunotherapeutics are administered by subcutaneous injection, Curalogic has developed a more convenient orally administered drug.
Timolol
go.drugbank.com/drugs/DB00373ApprovedInvestigational[L6724] It is also used in tablet form as a drug to treat hypertension.[L6727] Timolol was first approved by the FDA in 1978. … [L6724] This drug is marketed by several manufacturers [L6736] and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.
Talmapimod
go.drugbank.com/drugs/DB05412InvestigationalIt has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.
PBI-1402
go.drugbank.com/drugs/DB05480ExperimentalSince it stimulates immune activity, it has been considered as a candidate for cancer treatment as well as anemia. … PBI-1402 has a dual therapeutic action; as a chemoprotectant and hematopoietic progenitor stimulator.
S-8510
go.drugbank.com/drugs/DB06504ExperimentalIt was being codeveloped by Shionogi and GlaxoSmithKline.
Tocilizumab
go.drugbank.com/drugs/DB06273ApprovedInvestigational[L12789] It was later approved by Health Canada on 30 April 2010. … [A193281] Tocilizumab was granted FDA approval on 8 January 2010 to treat a number of inflammatory and autoimmune disorders, such as different types of arthritis and cytokine release syndrome.
Golodirsen
go.drugbank.com/drugs/DB15593ApprovedInvestigational[L10755,L10758] Golodirsen was initially rejected for FDA approval over concerns about its potential renal toxicity, however, clinical trials did not show significant toxicity.[L10755] … [L10773] Golodirsen was developed by Sarepta Therapeutics and granted accelerated FDA approval on December 12, 2019 due to the urgent need for this drug in patients suffering from a certain form of
Diloxanide
go.drugbank.com/drugs/DB08792ExperimentalDiloxanide (as [Diloxanide furoate]) is an anti-protozoal drug used in the treatment of Entamoeba histolytica and some other protozoal infections. … Although it is not currently approved for use in the United States, it was approved by a CDC study in the treatment of 4,371 cases of Entamoeba histolytica from 1977 to 1990.